Clinical trial
Safety Study to Evaluate Daptomycin in Non-infected Adults Who Are Either on…
NCT00490737 · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry · Completed
Key facts
| NCT number | NCT00490737 |
|---|---|
| Title | Safety Study to Evaluate Daptomycin in Non-infected Adults Who Are Either on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis (MK-3009-021) |
| Official title | An Evaluation of the Pharmacokinetic Profile and Safety and Tolerability of Multiple Doses of 6mg/kg Intravenous Daptomycin in Non-Infected Adult Subjects With End Stage Renal Disease on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis |
| Lead sponsor | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | End-Stage Renal Disease |
| Intervention type | Drug |
| Interventions | daptomycin |
| Enrollment | 12 |
| Start date | Aug 12, 2007 |
| Primary completion | May 12, 2008 |
| Completion | May 12, 2008 |
| First posted | Jun 25, 2007 |
| Last update posted | Jan 9, 2018 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: